Doxorubicin Cardiomyopathy

descriptionPublicationkeyboard_double_arrow_right Article 11 Dec 2009 English Publisher:S. Karger AGJournal:Cardiology, volume 115, pages 155-162 (issn: 0008-6312, eissn: 1421-9751,

Copyright policy )

Authors: Kanu, Chatterjee; Jianqing, Zhang; Norman, Honbo; Joel S, Karliner;

doi: 10.1159/000265166

pmid: 20016174

pmc: PMC2848530

Doxorubicin Cardiomyopathy

- Summary
- Subjects
- Metrics

Abstract

Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%. Extensive research has been done to understand the mechanism and pathophysiology of doxorubicin cardiomyopathy, and considerable knowledge and experience has been gained. Unfortunately, no effective treatment for established doxorubicin cardiomyopathy is presently available. Extensive research has been done and is being done to discover preventive treatments. However an effective and clinically applicable preventive treatment is yet to be discovered.

Related Organizations

University of Iowa
United States

Keywords

Antibiotics, Antineoplastic, Doxorubicin, Myocardium, Humans, Cardiomyopathies

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	945
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 0.1%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 1%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%